Showing results (31-40 of 218) with videos related to
Sort By:
Pageof 22
Nature Communications|February 5, 2024
Single-cell insights into immune dysregulation in rheumatoid arthritis flare versus drug-free remissionKenneth F Baker, David McDonald, Gillian Hulme, et al.Nature Reviews. Rheumatology|August 3, 2011
Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?Gillian M Bell, Gary Reynolds, John D IsaacsCurrent Opinion in Hematology|May 7, 2009
Regulatory T cells and autoimmunityJosephine Vila, John D Isaacs, Amy E AndersonAutoimmunity Reviews|April 9, 2026
Anti-CD52 therapy of rheumatic diseases: Revisited in the era of immune resetFadi Hassan, John D Isaacs, Mohammad E NaffaaBioengineering (Basel, Switzerland)|January 24, 2025
Exploring the Effect of Sampling Frequency on Real-World Mobility, Sedentary Behaviour, Physical Activity and Sleep Outcomes Measured with Wearable Devices in Rheumatoid Arthritis: Feasibility, Usability and Practical ConsiderationsJavad Sarvestan, Kenneth F Baker, Silvia Del DinRheumatology International|May 25, 2023
Number of days required to measure sedentary time and physical activity using accelerometery in rheumatoid arthritis: a reliability studyCiara M O'Brien, George D Kitas, Fiona Rayner, et al.Nature Reviews. Rheumatology|November 5, 2016
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkersPhilip M Brown, Arthur G Pratt, John D IsaacsNature Reviews. Rheumatology|December 15, 2015
Cytokines in rheumatoid arthritis - shaping the immunological landscapeIain B McInnes, Christopher D Buckley, John D IsaacsBest Practice & Research. Clinical Rheumatology|February 24, 2009
Current concepts in the pathogenesis of early rheumatoid arthritisArthur G Pratt, John D Isaacs, Derek L MatteyExpert Opinion on Investigational Drugs|September 1, 2009
Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?Robert J Moots, Andrew Jk Ostör, John D IsaacsPageof 22